Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
Operating Expenses Over TimeStrong
Percentile Rank85
3Y CAGR+8.6%
5Y CAGR+59.8%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+8.6%/yr
vs +15.2%/yr prior
5Y CAGR
+59.8%/yr
Recent deceleration
Acceleration
-6.7pp
Decelerating
Percentile
P85
Within normal range
vs 5Y Ago
10.4x
Strong expansion
Streak
1 yr
Consecutive declineStrong
| Period | Value | YoY Change |
|---|---|---|
| TTM | $66.60M | -3.9% |
| 2024 | $69.32M | +147.6% |
| 2023 | $27.99M | -46.2% |
| 2022 | $52.06M | -39.5% |
| 2021 | $86.04M | +1244.6% |
| 2020 | $6.40M | -72.7% |
| 2019 | $23.45M | -20.5% |
| 2018 | $29.52M | +122.2% |
| 2017 | $13.29M | -22.9% |
| 2016 | $17.23M | - |